Noveon

Noveome Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the restoration of cellular integrity in damaged or inflamed tissues. The company's primary asset, ST266, is a cell-free secretome derived from a proprietary population of amnion-derived epithelial cells that contains hundreds of biologically active proteins and growth factors. This multi-targeted therapeutic approach is designed to modulate inflammation, provide neuroprotection, and accelerate wound healing across diverse clinical applications. Noveome is currently advancing ST266 through clinical trials for indications in ophthalmology, neurology, and rare pediatric diseases.